Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab
| Autor: | Onder Tonyali, Mehmet Kucukoner, Halit Karaca, Suleyman Buyukberber, Mustafa Benekli, Ramazan Yildiz, Sinemis Yuksel, Ahmet Taner Sümbül, Berna Oksuzoglu, Arife Ulas, Asude Aksoy, Mevlude Inanc, Dogan Yazilitas, Yusuf Gunaydin, Mukremin Uysal, Tulay Akman, Ozgur Tanriverdi, Oznur Bal, Aydin Ciltas, Ugur Coskun, Umut Demirci |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Mastectomy Segmental Young Adult 03 medical and health sciences 0302 clinical medicine Breast cancer Risk Factors Trastuzumab Internal medicine Adjuvant therapy Humans Medicine Cumulative incidence Stage (cooking) skin and connective tissue diseases neoplasms Mastectomy Aged Neoplasm Staging Retrospective Studies Aged 80 and over Brain Neoplasms business.industry Incidence Retrospective cohort study General Medicine Middle Aged medicine.disease Logistic Models 030104 developmental biology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Surgery business Brain metastasis medicine.drug |
| Popis: | Purpose The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab. Methods Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively. Results Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER− and PR−) tumor ( p = 0.001, RR: 3.4, 95% CI: 1.33–8.71) and stage 3 disease ( p = 0.0032, RR: 9.39, 95% CI: 1.33–8.71) were significant risk factors for development of brain metastasis as the first site of recurrence. Conclusions In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER− and PR−) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|